Actively Recruiting
A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01)
Led by Obstetrics & Gynecology Hospital of Fudan University · Updated on 2025-10-02
1489
Participants Needed
14
Research Sites
268 weeks
Total Duration
On this page
Sponsors
O
Obstetrics & Gynecology Hospital of Fudan University
Lead Sponsor
P
Peking Union Medical College Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This observational study aims to establish a national cohort of patients with hydatidiform mole (molar pregnancy) to investigate its malignant transformation rate and malignant transformation mechanisms, with the goal of developing and promoting precision diagnosis and treatment models across China.
CONDITIONS
Official Title
A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinically or pathologically diagnosed as hydatidiform mole.
- Availability of complete medical records, including clinical and pathological data.
- No evidence of myometrial invasion or metastasis.
- Serum hCG levels normalized after uterine evacuation with at least 6 months of follow-up, OR diagnosed with postmolar gestational trophoblastic neoplasia during follow-up.
- No history of psychiatric disorders, serious infectious diseases, or immune system diseases such as systemic lupus erythematosus, myasthenia gravis, or HIV infection.
- Willing to participate in this study and sign the relevant informed consent form.
You will not qualify if you...
- Missing clinical data.
- Loss to follow-up: Do not return to participating hospital for follow-up visits after uterine evacuation, or could not be contacted for subsequent monitoring of hCG changes.
- Concomitant malignancies or autoimmune deficiency disorders such as systemic lupus erythematosus, myasthenia gravis, or HIV infection.
- Medical, psychological, social, occupational, or other conditions that would violate the study protocol or impair the subject's ability to provide informed consent, as determined by the investigator.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
Gansu Province Maternal and Child Care Hospital
Lanzhou, Gansu, China, 730050
Actively Recruiting
2
Shenzhen Maternity & Child Healthcare Hospital
Shenzhen, Guangdong, China, 518028
Not Yet Recruiting
3
Hainan women and children medical center
Haikou, Hainan, China, 570311
Actively Recruiting
4
Hebei Medical University Third Hospital
Shijiazhuang, Hebei, China, 050051
Not Yet Recruiting
5
Third Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450052
Not Yet Recruiting
6
Dalian Women and Children medical Center
Dalian, Liaoning, China, 116038
Not Yet Recruiting
7
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China, 110004
Not Yet Recruiting
8
Center for Reproductive Medicine, Shandong University
Jinan, Shandong, China, 250021
Not Yet Recruiting
9
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China, 266000
Not Yet Recruiting
10
Shanghai First Maternity and Infant Hospital
Shanghai, Shandong, China, 201204
Not Yet Recruiting
11
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, China, 200090
Actively Recruiting
12
First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China, 310003
Not Yet Recruiting
13
Peking Union Medical College Hospital
Beijing, China, 100730
Actively Recruiting
14
International Peace Maternity and Child Health Hospital
Shanghai, China, 200030
Not Yet Recruiting
Research Team
X
Xin Lu, MD & PhD
CONTACT
Y
Yan Du, DrPH
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here